Pharmaceuticals - Indian - Bulk Drugs & Formln M/S
No data available
No data available
No data available
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Total Revenue | 482.10 | 647.39 | 681.33 | 663.90 | 416.54 |
Total Expenses | 454.45 | 569.20 | 591.65 | 545.08 | 380.48 |
Profit Before Tax | -16.68 | 78.18 | 89.68 | 118.82 | 36.06 |
Profit After Tax | -14.33 | 63.53 | 71.39 | 83.11 | 25.24 |
Operating Profit after Depreciation | 57.33 | 95.74 | 102.31 | 127.12 | 42.51 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Fixed Assets | 254.57 | 367.07 | 269.74 | 208.13 | 162.24 |
Total Non Current Assets | 360.59 | 397.26 | 322.79 | 267.30 | 174.53 |
Total Current Assets | 404.54 | 500.40 | 398.31 | 258.33 | 168.42 |
TOTAL ASSETS | 765.13 | 897.66 | 721.10 | 525.63 | 342.95 |
Total Shareholder's Fund | 278.36 | 367.69 | 328.49 | 258.41 | 177.93 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Net Cash from Operating Activities | 92.29 | -22.19 | 0.69 | 43.56 | 20.57 |
Net Cash used in Investing Activities | -11.24 | -93.43 | -74.80 | -108.93 | -27.56 |
Net Cash used in Financing Activities | -96.60 | 131.37 | 61.85 | 75.46 | 3.28 |
No data available
Particulars (in ₹ Cr.) | 2024-12 | 2024-09 | 2024-06 | 2024-03 | 2023-12 |
---|---|---|---|---|---|
Total Revenue | 122.79 | 133.09 | 132.25 | 133.90 | 108.57 |
Total Expenses | 104.39 | 108.56 | 108.63 | 117.86 | 96.76 |
Profit Before Tax | 8.41 | 13.57 | 9.30 | -33.07 | -1.39 |
Profit After Tax | 11.72 | 9.46 | 7.13 | -29.92 | -2.20 |
Operating Profit after Depreciation | 20.77 | 28.26 | 24.47 | 24.57 | 12.61 |
₹1/Share
Company | Price | Market Cap (in ₹ Cr) |
---|---|---|
Bajaj Healthcare Ltd | ₹590.70 | ₹1,865.62 |
Sun Pharmaceuticals Industries Ltd | ₹1,699.75 | ₹4,07,826.96 |
Divis Laboratories Ltd | ₹5,949.15 | ₹1,57,931.24 |
Cipla Ltd | ₹1,452.70 | ₹1,17,322.09 |
Torrent Pharmaceuticals Ltd | ₹3,104.95 | ₹1,05,080.90 |
Mankind Pharma Ltd | ₹2,451.35 | ₹1,01,134.59 |
On 11 February 2025
07 Feb 2025, 10:48 am
Bajaj Healthcare said that it has received approval from the Drug Controller General of India (DCGI) to manufacture both the API and drug formulation of Pimavanserin.
30 Jan 2025, 01:32 pm
30 Jan 2025, 09:24 am
Bajaj Healthcare soared 13.41% to Rs 637.25 after the company said that it has received exclusive rights for manufacturing, distribution & sales of the finished formulation of the product magnesium L Threonate (Magtein) in India from Threotech LLC.
17 Jan 2025, 11:50 am
Bajaj Healthcare rallied 3.63% to Rs 447.75 after the company's Active Pharmaceutical Ingredient (API) manufacturing site at Savli, Vadodara in Gujarat received approval from Therapeutic Goods Administration (TGA), Australia.
09 Dec 2024, 12:39 pm